A Phase 4 Single-arm Open-label Study for the Efficacy and Safety of Prolia® in Subjects With Glucocorticoid-induced Osteoporosis in Mainland China
Latest Information Update: 01 Jun 2026
At a glance
- Drugs Denosumab (Primary)
- Indications Osteoporosis
- Focus Therapeutic Use
- Sponsors Amgen
Most Recent Events
- 27 May 2026 Planned End Date changed from 24 May 2027 to 27 Apr 2027.
- 27 May 2026 Planned primary completion date changed from 24 May 2027 to 27 Apr 2027.
- 27 May 2026 Status changed from recruiting to active, no longer recruiting.